August 04, 2026

U.S. News & World Report Names Dana-Farber Brigham Cancer Center #1 Locally, #3 Nationally for 2026-2027

Dana-Farber Brigham Cancer Center has been recognized as the Best Hospital for Cancer in Massachusetts and ranked #3 in the nation by U.S. News & World Report. This is the 26th consecutive year Dana-Farber Brigham has been recognized for its excellence in caring for people with cancer.

Dana-Farber

July 31, 2026

Lung Cancer Care in 2026: Earlier Detection, Earlier Intervention, More Individualized Treatment

Lung cancer care is entering a more precise and increasingly proactive era. While the disease remains a leading cause of cancer mortality, earlier detection through low-dose CT screening, broader use of molecular profiling and rapid advances in targeted therapy and immunotherapy are changing how patients are diagnosed, staged and treated.

Baptist Health South Florida

July 16, 2026

Dana-Farber Researchers Identify CDK8 as a Potential Therapeutic Target for Alveolar Rhabdomyosarcoma

Dana-Farber Cancer Institute researchers studied alveolar rhabdomyosarcoma (aRMS), an aggressive childhood cancer with poor survival and few targeted treatment options, to identify new treatment vulnerabilities. Using a network-based analysis of large functional genomic datasets, they found that aRMS cells depend on CDK8, a protein involved in controlling gene activity.

Dana-Farber

July 08, 2026

Surgical Manual from Roswell Park Created to Advance Bladder Cancer Surgery Worldwide

Roswell Park Comprehensive Cancer Center announces the release of a new operative surgical manual authored by Khurshid Guru, MD.

Roswell Park Comprehensive Cancer Center

July 07, 2026

Baptist Health Cancer Care to Present Research on Precision Radiation Therapy Across Complex Cancers at ASTRO 2026

Experts across Baptist Health Herbert Wertheim Cancer Institute and Eugene M. & Christine E. Lynn Cancer Institute will present new radiation oncology research and clinical expertise at the 2026 Annual Meeting of the American Society for Radiation Oncology (ASTRO), September 26-30, 2026, in Boston.

Baptist Health South Florida

July 06, 2026

Dana-Farber Research Supports FDA Approval of New Therapy for “Double-Positive” Metastatic Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved a new therapy regimen for patients with “double-positive” metastatic breast cancer based on results of the phase 3 PATINA study led by Otto Metzger, MD, Associate Medical Director of International Strategic Initiatives at Dana-Farber Cancer Institute.

Dana-Farber

July 02, 2026

2026 ASCO Kidney Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates

Dana-Farber

July 02, 2026

2026 ASCO Bladder Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates

Dana-Farber

July 02, 2026

2026 ASCO Prostate Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates.

Dana-Farber

July 01, 2026

ASCO26: Alicia Morgans, MD, MPH, ARACOG

Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.

Dana-Farber